This SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Illuminate Therapeutics, Inc. to develop the LADDR platform for precise delivery of nucleic acid therapy for head and neck and esophageal cancers.
The key objectives are to: 1) identify miRNA-mimic-responsive and non-responsive patient-derived tumors, 2) select predictive biomarkers for responsive tumors, and 3) determine the pharmacokinetics and pharmacodynamics of the LADDR vehicle for delivering functional miRNA mimics to tumors in vivo. This research aims to derisk the commercialization of the LADDR technology by addressing two major challenges - predicting responsive and non-responsive tumors, and understanding the impact of administration route on the platform's properties. The insights gained will support the development of personalized miRNA-based cancer therapies using the LADDR delivery system.
Generated 1/28/25, 10:24 AM